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Rifapentine is a potent antituberculosis drug currently in phase III trials. Bioavailability decreases with increasing dose, yet high
daily exposures are likely needed to improve efficacy and shorten the tuberculosis treatment duration. Further, the limits of tol-
erability are poorly defined. The phase I multicenter trial in healthy adults described here investigated two strategies to increase
rifapentine exposures: dividing the dose or giving the drug with a high-fat meal. In arm 1, rifapentine was administered at 10
mg/kg of body weight twice daily and 20 mg/kg once daily, each for 14 days, separated by a 28-day washout; the dosing sequence
was randomized. In arm 2, 15 mg/kg rifapentine once daily was given with a high-fat versus a low-fat breakfast. Sampling for
pharmacokinetic analysis was performed on days 1 and 14. Population pharmacokinetic analyses were performed. This trial was
stopped early for poor tolerability and because of safety concerns. Of 44 subjects, 20 discontinued prematurely; 11 of these
discontinued for protocol-defined toxicity (a grade 3 or higher adverse event or grade 2 or higher rifamycin hypersensitiv-
ity). Taking rifapentine with a high-fat meal increased the median steady-state area under the concentration-time curve
from time zero to 24 h (AUC0 –24ss) by 31% (relative standard error, 6%) compared to that obtained when the drug was
taken with a low-fat breakfast. Dividing the dose increased exposures substantially (e.g., 38% with 1,500 mg/day).
AUC0 –24ss was uniformly higher in our study than in recent tuberculosis treatment trials, in which toxicity was rare. In
conclusion, two strategies to increase rifapentine exposures, dividing the dose or giving it with a high-fat breakfast, suc-
cessfully increased exposures, but toxicity was common in healthy adults. The limits of tolerability in patients with tuber-
culosis remain to be defined. (AIDS Clinical Trials Group study A5311 has been registered at ClinicalTrials.gov under reg-
istration no. NCT01574638.)
In 2013, there were an estimated 9.0 million new cases of tuber-culosis (TB) and 1.5 million TB-related deaths worldwide (1).
Although effective treatment is available, standard short-course
therapy with isoniazid, rifampin, pyrazinamide, and ethambutol
must be given for 6 months to be effective. Rifampin, a rifamycin
antibiotic, is a cornerstone of modern first-line regimens because
rifamycins have unique sterilizing activity against TB. In the ab-
sence of rifampin, treatment must be prolonged to 12 to 24
months, as no drug has proven clinical activity sufficient to replace
it. Current dosing of rifampin yields concentrations that are on
the steep slope of the dose-response curve (2–5). Optimization of
rifamycins represents a promising path toward TB treatment
shortening.
The rifamycin antibiotic rifapentine (RPT) has a longer half-
life and a lower MIC against Mycobacterium tuberculosis than ri-
fampin. It is being investigated as a potent anti-TB drug that may
help shorten the treatment duration. In mouse models of TB, RPT
is about four times more potent than rifampin, and its activity is
dose dependent; daily RPT-containing regimens cure TB in 3
months or less (6, 7). In immune-deficient mice, RPT renders
mice culture negative more rapidly than the standard dose of ri-
fampin and better protects against the emergence of resistance to
companion drugs (8).
In previous trials that evaluated different RPT dose schedules
for pulmonary TB, daily doses up to 20 mg/kg of body weight
given with food were effective and well tolerated; however, the
maximum tolerated dose (MTD) has not been defined (9, 10).
Notably, in those studies, dose escalations did not proportionally
increase the mean steady-state RPT concentrations, which pla-
teaued in the 15-mg/kg arm. Clinical trials aimed at testing the
highest well-tolerated dose of RPT are thus justified by preclinical
data that demonstrate the concentration-dependent treatment-
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shortening activity of the drug, its activity in immune deficiency,
and its ability to protect against the development of resistance to
companion drugs. Since strategies with doses higher than 10
mg/kg daily are needed to optimize RPT efficacy but concentra-
tions may plateau with a dose of 15 mg/kg, we designed this trial to
evaluate the safety and pharmacokinetics (PKs) of two strategies
intended to increase RPT plasma exposures without increasing
the total daily dose: dividing the dose and giving RPT with a glob-
ally available, inexpensive food (a boiled egg) to increase absorp-
tion (11).
MATERIALS AND METHODS
Study population. Healthy adults 18 to 65 years of age were recruited at
four AIDS Clinical Trials Group (ACTG) sites in the United States be-
tween June 2012 and May 2013. Inclusion criteria were a weight of 50 to
100 kg, alanine aminotransferase and total bilirubin concentrations 1.2
times the upper limit of normal, a serum creatinine concentration of 1.5
mg/dl, a platelet count of 125,000/mm3, an absolute neutrophil count of
1,250/mm3, a serum albumin concentration of 3.5 g/dl, negative HIV
and hepatitis C virus antibody tests, and no active TB or history of TB. The
study was approved by the institutional review boards of the participating
sites; all participants provided written informed consent. ACTG study
A5311 has been registered at ClinicalTrials.gov under registration no.
NCT01574638.
Experimental protocol. (i) Study design. This was a phase I, open-
label, two-arm, crossover study. In group 1 we evaluated divided dosing,
and in group 2 we evaluated meal type (Fig. 1). In arm 1A, participants
received RPT at 10 mg/kg twice daily for 14 days, followed by a 28-day
washout, and then RPT at 20 mg/kg once daily for 14 days. Participants in
arm 1B received the same regimens but in reverse order: RPT at 20 mg/kg
once daily, followed by a washout, and then RPT at 10 mg/kg twice daily.
In arm 1, doses were taken with a low-fat meal. Participants in arm 2A
received RPT at 15 mg/kg once daily for 14 days with an egg, which served
as a proxy for a high-fat meal, followed by a 28-day washout, and then
RPT at 15 mg/kg once daily for 28 days with a low-fat breakfast. In arm 2B,
participants received RPT at 15 mg/kg once daily for 14 days with a low-fat
breakfast, followed by a 28-day washout, and then RPT at 15 mg/kg once
daily for 14 days with an egg. Individuals available to participate in pro-
longed dosing were assigned to arm 2A. All other participants were ran-
domized 1:1:1 to arm 1A, 1B, or 2B. Intensive sampling for analysis of the
PKs of RPT and its less active deacetyl metabolite (desacetyl-rifapentine
[desRPT]) was performed following the 1st and 14th doses in each dosing
period. In arm 2A, sampling was performed on days 1, 14, and 28 during
the final dosing period (to assess the time to steady state). For twice-daily
dosing, sampling times were predose; at 0.5, 1, 2, 4, 5, 8, and 12 h after the
a.m. dose; and at 2, 4, and 12 h following the p.m. dose. For once-daily
dosing, samples were collected predose and at 0.5, 1, 2, 4, 5, 8, 12, and 24
h postdose.
(ii) Safety monitoring. Participants underwent safety evaluations ap-
proximately weekly. Signs, symptoms, and laboratory events were graded
according to the Division of AIDS Table for Grading the Severity of Adult
and Pediatric Adverse Events, Version 1.0 (December 2004, August 2009
clarification) (12).
(iii) Criteria for premature treatment discontinuation. The study
drug was discontinued for grade 3 or higher drug-related adverse events
(AEs) or for grade 2 or higher rifamycin hypersensitivity syndrome
(RHS). Consistent with other RPT trials, RHS was defined as either (i)
hypotension, urticaria, angioedema, acute bronchospasm, or conjuncti-
vitis that occurred in relation to study drug or (ii) more than 4 of the
following (with one being grade 2 or higher) occurring in relation to study
drug: weakness, fatigue, nausea, vomiting, headache, fever, aches, sweats,
dizziness, shortness of breath, flushing, or chills (10, 13, 14).
Measurement of RPT and desRPT in plasma. The liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) method used to quantify
drug was based on a previously described method (9). Briefly, RPT and
desRPT were eluted under reversed-phase conditions with 5 mM ammo-
nium formate in water (mobile phase A) and 3% dimethyl sulfoxide in
acetonitrile (mobile phase B). Ascorbic acid (0.5 mg/ml) in extraction
solvents prevented the drugs from becoming oxidized to form quinones.
RPT and desRPT were detected over a 4.0-min run using an AB-Sciex
QTRAP 5500 mass analyzer (Foster City, CA) interfaced with a Waters
Acquity ultraperformance liquid chromatography (UPLC) system (Mil-
ford, MA). The ion transitions monitored for RPT, desRPT,and isotopi-
cally labeled rifampin (internal standard) were m/z 877.6 ¡ m/z 845.5,
m/z 835.5 ¡ m/z 803.5, and m/z 826.6 ¡ m/z 749.5, respectively. Analyt-
ical ranges for both RPT and desRPT were 50 to 80,000 ng/ml. Intraday
precision and accuracy for RPT and desRPT were 8.81% and 13.5%,
respectively, and interday precision and accuracy were 10.8% and
11.3%, respectively.
Pharmacogenetic testing. Genotyping of two targeted polymor-
phisms in the membrane transporter gene SLCO1B1, rs4149056 521T ¡
C and rs4149032 C¡T, was performed by the TaqMan assay with an ABI
Prism 7900 HT sequence detection system (Applied Biosystems, Inc., Fos-
ter City, CA). The former polymorphism was found to be associated with
increased plasma concentrations of statins and other drugs (15), and the
latter was found to be associated with decreased plasma rifampin concen-
trations in patients with TB in South Africa (16).
PK and statistical analyses. (i) Sample size. We estimated that 20
evaluable volunteers in each group would provide at least a 90% power to
FIG 1 Study schema.
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detect at least a 25% mean difference in the RPT steady-state area under
the concentration-time curve from time zero to 24 h (AUC0 –24ss) using a
nonparametric paired-sample Wilcoxon test with a type I error rate of
0.05. We aimed to enroll at least 24 volunteers per group (12 persons each
completing study arms 1A, 1B, 2A, and 2B) to ensure 20 PK-evaluable
participants per group.
(ii) PK and statistical evaluation. PK parameters for RPT and
desRPT, including AUC0 –24ss, the maximum concentration in plasma
(Cmax), the time to the maximum concentration in plasma (Tmax), half-
life (t1/2), and oral clearance (CL/F), were determined using standard
noncompartmental analysis (NCA) methods performed in SAS (SAS In-
stitute Inc., Cary, NC). Statistical analyses for PK comparisons were based
on nonparametric tests.
(iii) Population PKs and PK-toxicity analyses. In addition to NCA,
population PK modeling was planned a priori to strengthen and expand
knowledge of RPT PKs. The population PK model was developed using
nonlinear mixed effect modeling, implemented in NONMEM software.
Previously described model structure and model-building procedures
were used (17). In brief, parent and metabolite data were fitted simulta-
neously. A one-compartment disposition model was used for both the
parent drug and the metabolite. RPT absorption was described using a
transit compartment model. The relationship between relative bioavail-
ability and dose was quantified to describe the change in bioavailability
with increased dose. Since the numbers of individuals that received the
same dose level were small, a separate bioavailability parameter was esti-
mated for dose groups classified as low (600 and 750 mg), medium (900,
1,050, and 1,200 mg), and high (1,350, 1,500, and 1,800 mg). The param-
eter describing the increase in bioavailability when RPT was dosed with an
egg compared to that when it was dosed with a low-fat breakfast was
estimated separately. An autoinduction model describing the increase in
clearance (CL) over time was implemented. Individual parameters were
assumed to be log-normally distributed, and residual error was assumed
to be proportional. All data were analyzed using the nonlinear mixed
effects approach available in NONMEM (version 7.3; Icon Development
Solutions, Ellicott City, MD). The first-order conditional estimation with
interaction (FOCEI) method was employed throughout the analyses. The
model-building procedure was guided by the likelihood ratio test, diag-
nostic plots, and internal model validation techniques, including visual
and numerical predictive checks.
RESULTS
Study subjects. Forty-four participants were enrolled. More par-
ticipants opted for longer-duration trial participation, so more
were assigned to arm 2A than were randomized to arm 1A, 1B, or
2B (Fig. 2). The median age was 35 years, and the median weight
was 83 kg; 27% were women, and 32% were black non-Hispanic
(Table 1). The median total daily RPT dose was 1,350 mg (range,
900 to 1,800 mg).
Safety and tolerability. Of 44 participants, 20 discontinued
prematurely; 11 of these discontinued for protocol-defined toxic-
ity (a grade 3 or higher AE or grade 2 or higher RHS) (Fig. 2).
There were no serious adverse events (SAEs). Reasons for discon-
tinuation by arm and by dose (in milligrams) are presented in
Table 2. Of 16 participants receiving RPT at 10 mg/kg twice daily
at any time, 7 (44%) discontinued early. For doses of 15 mg/kg
with a low-fat breakfast, 15 mg/kg with an egg, and 20 mg/kg once
daily, rates of discontinuation were 5/23 (22%), 5/25 (20%), and
3/13 (23%), respectively. Of 7 participants receiving 1,800 mg, 5
(71%) discontinued because of toxicity. There was no apparent
association between period (i.e., before versus after washout) and
the risk of discontinuation (data not shown), and most protocol-
defined toxicities occurred early in the dosing period (the first 1 to
3 days). While there were no prespecified halting rules, tolerability
was poor, and the study was stopped early because of safety con-
cerns. A summary of protocol-defined toxicities is provided in
Table 3.
Pharmacokinetics of RPT. Participants who completed visits
for PK analysis were included in the PK analyses even if they did
not complete the entire study. Median (interquartile ratio [IQR])
steady-state RPT PK parameters are shown in Table 4. We did not
meet the target sample size required to evaluate dosing strategies
FIG 2 Consort diagram. BID or bid, twice daily; QD or qd, once daily; LFB, low-fat breakfast.
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using intraparticipant comparisons of NCA-derived AUC0 –24ss,
so those analyses were not performed. Rather, results from pre-
specified modeling analyses are reported.
Population PK modeling. Model-based estimates of steady-
state RPT exposures are presented in Table 5. Full model param-
eters are provided in Table S1 in the supplemental material. Tak-
ing RPT with an egg increased RPT bioavailability by 31%
(relative standard error [RSE], 6%). Bioavailability decreased with
increased dose; the bioavailabilities of medium doses (900 and
1,200 mg) and high doses (1,350 mg, 1,500 mg, and 1,800 mg)
were estimated to be 0.84 and 0.64, respectively, confirming that if
a high dose is required, dividing the dose is a reasonable strategy to
capitalize on the better bioavailability of lower dose levels. For
example, for a dose of 1,500 mg, dividing the dose increased the
AUC0 –24ss by 38%. Covariates that affected exposures included
diet and dose (each affected bioavailability). In the model, the
SLCO1B1 rs4149056 and rs4149032 C alleles were each associated
with decreased clearance, but statistical significance was not
reached (P  0.25 for each). With single-dose data, the rs4149056
CT and CC genotypes were associated with 10% and 21% lower
median RPT clearances, respectively, versus the clearance for the
rs4149056 TT genotype, while the rs4149032 CT and CC geno-
types were associated with 7% and 15% lower clearances, respec-
tively, versus the clearance for the rs4149032 TT genotype. With
multiple-dose data, the rs4149056 CT and CC genotypes were
associated with 14% and 21% lower mean RPT clearances, respec-
tively, versus the clearance for the rs4149056 TT genotype, but for
rs4149032 there was a 5% apparent difference in the mean clear-
ance between the CC, CT, and TT genotypes. Steady state ap-
peared to be reached by the end of the second week, when auto-
induction seemed to be complete; estimates of CL did not
TABLE 1 Characteristics of study participantsa
Characteristic Value
Median (range) age (yr) 35 (20–59)
No. (%) of participants of the following gender:
Male 32 (73)
Female 12 (27)
No. (%) of participants of the following race/ethnicity:
Black non-Hispanic 14 (32)
White non-Hispanic 20 (45)
Hispanic 6 (14)
Asian, Pacific Islander 2 (5)
Not reported 2 (4)
Median (range) wt (kg) 83 (60–99)
Median (range) BMIb (kg/m2) 27 (20–35)
No. (%) of participants with the following SLCO1B1









a Data are for 44 participants.
b BMI, body mass index.












10 mg/kg BID 16 7 (44) 4 1 1 1
15 mg/kg QD with an LFB 23 5 (22) 3 1 1 0
15 mg/kg QD with an egg 25 5 (20) 2 1 2 0
20 mg/kg QD 13 3 (23) 2 0 0 1
Total daily dose (mg)
900 mg 4 4 (100) 2 0 2 0
1,200 17 6 (35) 3 1 1 1
1,350 12 3 (25) 1 1 1 0
1,500 4 1 (25) 1 0 0 0
1,800 7 6 (86) 4 1 0 1
a BID, twice daily; QD, once daily; LFB, low-fat breakfast.
b Number of participants who received this regimen at any time.
c Discontinuations among participants receiving this regimen.
TABLE 3 Summary of protocol-defined toxicities, defined as grade 3 or
higher drug-related AEs or grade 2 or higher RHS
Arm
Total daily
dose (mg) Adverse event
Highest
AE grade
1A 1,800 Neutropenia 3
1A 1,500 RHS 2
1A 1,800 RHS 3
1A 1,800 Elevated alanine aminotransferase 4
1B 1,200 RHS 3
1B 1,800 RHS 2
2A 1,350 Lymphopenia 3
2A 1,200 RHS 3
2A 1,200 Neutropenia 3
2B 900 RHS, elevated alanine aminotransferase 3
2B 900 Headache with nausea, vomiting, fatigue 3
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significantly increase after 14 days of daily treatment in arm 2A
participants receiving prolonged daily dosing.
DISCUSSION
Two dosing strategies, dividing the dose and giving the dose with
a boiled egg, successfully increased RPT exposures. However,
these high exposures were poorly tolerated in this trial, which
enrolled healthy volunteers without TB. Protocol-defined toxici-
ties, including RHS, were common, and the trial was terminated
early for safety concerns. We identified a possible association be-
tween the SLCO1B1 rs4149056 521T ¡ C allele and decreased
RPT clearance, consistent with the known association of this poly-
morphism with plasma exposure of statins and other drugs (15),
but the small sample size limited our ability to demonstrate statis-
tical significance or to stratify analyses by race/ethnicity.
Rifamycins drive the treatment response for TB, and with the
doses currently used or tested clinically, higher doses are more
efficacious (5, 18, 19). This appears to be the case for both rifam-
pin and RPT. For rifampin, increasing the dose results in suprap-
roportional increases in plasma drug concentrations (4). In con-
trast, RPT bioavailability decreases with increasing dose (17), so
alternative strategies to increase exposures are needed. To maxi-
mize the likelihood of success with RPT-containing shorter-dura-
tion regimens, the relationships between exposure and microbio-
logic response must be better understood and fully characterized.
PK/pharmacodynamic (PD) analyses from recent phase II clinical
trials are helping to define this target for RPT (10, 14, 18). Studies
such as the present one are valuable because they provide strate-
gies for achieving these target concentrations in the largest possi-
ble number of patients.
A shortened TB treatment duration benefits patients and pub-
lic health systems by reducing the logistical burdens of treatment
delivery. However, strategies such as providing a boiled egg or
giving a drug twice daily (or other interventions designed to max-
imize the success of a shortened regimen) add logistical concerns.
Models suggest that a regimen of 4 months or shorter would be
cost-effective in most settings (20), but we know little about the
value that health care workers and patients place on treatment
shortening and acceptable trade-offs in exchange for reduced
treatment time.
Higher doses of rifamycins are desirable to improve efficacy,
but their impact on safety and tolerability is unknown. In Tuber-
culosis Trials Consortium (TBTC) study 29X, a recently com-
pleted phase II trial of RPT given at doses ranging from 10 to 20
mg/kg daily with food and concomitant isoniazid, pyrazinamide,
and ethambutol during the first 8 weeks of TB treatment (14),
participants with TB receiving 15 mg/kg once daily had a median
AUC0 –24ss of 406 g · h/ml, and participants receiving 20 mg/kg
had a median exposure of 580 g · h/ml, lower than the exposures
in the current study of healthy volunteers (18). RPT was very well
tolerated in TBTC study 29X, with only 3 discontinuations for
toxicity in the 15- and 20-mg/kg arms (because of grade 2 nausea
in 1 of 81 participants receiving 15 mg/kg and because of hepatitis
and drug allergy 2 of 81 participants receiving 20 mg/kg) (14). The
difference in exposures in our study compared with those in
TBTC study 29X may be due to differences in participants’
weights. Weight does not significantly impact RPT oral clearance
(17), which means that higher-weight individuals (such as the
healthy volunteers in our trial) receive higher doses (in milli-
grams) and have higher exposures than lower-weight individuals
(such as patients with TB) for the same milligram-per-kilogram
dose (the median dose in TBTC study 29X was 900 mg; in ACTG
study A5311 it was 1,350 mg). In addition, in our study the inten-
tion was to increase exposures by dividing the dose or giving the
dose with a meal type known to enhance absorption (11). High-fat
meals may improve the absorption of lipophilic drugs by increas-
ing their solubility, thus enhancing their passive diffusion through
enterocytes, and drugs may also associate with triglyceride-rich
lipoproteins in high-fat meals with eggs, which facilitates absorp-
tion through the lymphatics system. Also, in TBTC study 29X,
TABLE 4 Pharmacokinetic parameters for RPT and desRPT among ACTG study A5311 participants using NCAa
Pharmacokinetic parameter Dosing cohort No. of participants
RPT desRPT
Median IQR Median IQR
AUC0–24ss (g · h/ml) 20 mg/kg QD 9 580 521–637 467 256–689
10 mg/kg BID 10 756 681–898 918 666–1,014
15 mg/kg with an LFB 19 689 611–860 556 487–803
15 mg/kg with an egg 19 715 577–1,037 687 537–932
Cmin (g/ml) 20 mg/kg QD 9 13 1–17 10 0.5–23
10 mg/kg BID 10 22 19–30 27 19–35
15 mg/kg with an LFB 19 14 12–25 13 11–21
15 mg/kg with an egg 19 18 13–23 22 15–29
Cmax (g/ml) 20 mg/kg QD 9 39 32–45 25 14–37
10 mg/kg BID 10 39 35–44 44 34–48
15 mg/kg with an LFB 19 42 34–49 30 24–40
15 mg/kg with an egg 19 44 36–61 38 28–46
a QD, once daily; BID, twice daily; LFB, low-fat breakfast; Cmin, minimum concentration in plasma.
TABLE 5 Model-based estimates of steady-state RPT exposures for
different dosing schemes
Regimena Median AUC0–24ss (g · h/ml)
900 mg QD with a low-fat breakfast 552
900 mg QD with an egg 718
1,500 mg QD with a low-fat breakfast 589
750 mg BID with a low-fat breakfast 920
a QD, once daily; BID, twice daily.
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rifapentine was given with companion drugs, which may have
affected the absorption of rifapentine.
There are several possible reasons for the higher rates of ad-
verse events (AEs) in our study than the rates observed in TBTC
study 29X. These include higher drug exposures, a lower threshold
for defining a dose-limiting toxicity (drug was stopped in any
participant who met the case definition of RHS and had a grade 2
or higher AE), the easier attribution of drug-related adverse events
in healthy volunteers than in patients with TB-related symptoms,
geographic or genetic differences in patient populations, or, per-
haps, more robust immunologic responses. It is unclear whether
RHS or other rifamycin-related toxicities (e.g., cytopenia or hep-
atotoxicity) are more common among healthy volunteers than
among persons with TB and/or HIV infection (21, 22) or if pa-
tients with TB would have similar toxicities if they had exposures
similar to those for the participants in this study. Further, an un-
derlying mechanism(s) for rifamycin-induced cytopenias, hepa-
totoxicity, and RHS remains elusive (23, 24). In ACTG study
A5311, RHS symptoms resolved quickly, and no individuals with
RHS required hospitalization.
This study had limitations. It was stopped early, so target ac-
crual was not achieved. Therefore, NCA estimates of PK values
were imprecise and the sample size was insufficient to make reli-
able within-arm, intraindividual comparisons; however, popula-
tion modeling analyses that used data from all participants in all
arms provided valuable information about the effects of food type
and dosing frequency on PK parameters. This study exemplifies
how incorporating model-based PK and PK/PD analyses into the
study design can provide unforeseen benefits. The fact that more
participants opted for arm 2A because of its higher remuneration
may have introduced some bias. However, protocol-defined tox-
icity was objectively assessed and graded, and PK evaluations
should not be subject to bias.
In conclusion, dividing the RPT dose or giving RPT with an egg
increased RPT exposures among healthy volunteers, but frequent
toxicities, including RHS, led to early study termination. A possi-
ble reason for the poorer tolerability in our study than in recent
phase II studies in patients with TB was the much higher plasma
RPT exposures. The limits of tolerability among patients with TB
who achieve RPT exposures similar to those in this trial are un-
known and must be assessed prospectively.
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